Search

Your search keyword '"Ileana S. Mauldin"' showing total 47 results

Search Constraints

Start Over You searched for: Author "Ileana S. Mauldin" Remove constraint Author: "Ileana S. Mauldin"
47 results on '"Ileana S. Mauldin"'

Search Results

1. Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas

2. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma

3. Proliferating CD8+ T Cell Infiltrates Are Associated with Improved Survival in Glioblastoma

4. Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma

5. Perivascular Adipose Tissue Harbors Atheroprotective IgM-Producing B Cells

6. CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab

10. Data from Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival

11. 47 Tertiary lymphoid structures (TLS) in desmoplastic melanomas (DM) differ from non-DM-associated TLS by their intratumoral location and enhanced immune activity

12. Proliferating CD8

13. Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors

14. Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)

15. Immunotyping and Quantification of Melanoma Tumor-Infiltrating Lymphocytes

16. Multiplex Immunofluorescence Histology for Immune Cell Infiltrates in Melanoma-Associated Tertiary Lymphoid Structures

17. Multiplex Immunofluorescence Histology for Immune Cell Infiltrates in Melanoma-Associated Tertiary Lymphoid Structures

18. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma

19. Immunotyping and Quantification of Melanoma Tumor–Infiltrating Lymphocytes

20. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts

21. Deconvolution of the immunological contexture of mouse tumors with multiplexed immunohistochemistry

22. Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures

23. Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity

24. Proliferating CD8+ T Cell Infiltrates Are Associated with Improved Survival in Glioblastoma

25. 337 Intratumoral immune therapy for recurrent breast cancer with polyICLC, and tremelimumab combined with systemic durvalumab

26. 388 A trial to evaluate the safety, immunogenicity, and clinical activity of a helper peptide vaccine plus PD-1 blockade (Mel64, PATHVACS: PD-1 antibody and T-helper vaccine and correlative studies)

27. Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases

29. Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma

30. IMMU-69. PROGNOSTIC IMPLICATION OF B-CELL INFILTRATE IN PATIENTS WITH GLIOBLASTOMA (GBM)

31. TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10

32. Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases

33. The tyrosine phosphatase SHP-1 dampens murine Th17 development

35. Pilot trial of an Indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma

36. A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites

37. Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival

38. TLR2/6 agonists and IFN-gamma treatment induces favorable immune cell recruiting signatures from melanoma associated with STAT1 and IL-32 signaling

39. The protein tyrosine phosphatase SHP-1 modulates the suppressive activity of regulatory T cells

40. Cytokines and TLR agonists influence the expression of retention integrins CD49a, CD49b and CD103 by T cells

41. Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer

42. TLR2/6 agonists and IFNγ synergize to induce melanoma cells to produce T-cell recruiting chemokines

43. Pilot clinical trials testing the safety and effects on the metastatic melanoma microenvironment of intratumoral interferon-gamma or imiquimod, plus a multipeptide melanoma vaccine

45. Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)

46. Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma

47. Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment

Catalog

Books, media, physical & digital resources